Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GABRE | P78334 | 2/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641064 | 0.90 | MDM2 (0.57) | DAOGABRPGABRDADORA3GABRA1 | |
| SCHEMBL641668 | 0.86 | GABRP (0.51) | DAOGABRPGABRDADORA3GABRA1 | |
| SCHEMBL640676 | 0.85 | MDM2 (0.42) | PGRMDM2MEN1LMNAKMT2A | |
| SCHEMBL639654 | 0.85 | CBX7 (0.55) | DAOGABRPGABRDADORA3GABRA1 | |
| SCHEMBL641539 | 0.84 | TP53 (0.42) | DAOPGRMDM2LMNAB3GNT2 | |
| SCHEMBL27755968 | 0.84 | B3GNT2 (0.44) | DAOGABRPGABRDADORA3GABRA1 | |
| SCHEMBL639518 | 0.83 | POLB (0.57) | DAOGABRPGABRDADORA3GABRA1 | |
| SCHEMBL640979 | 0.82 | CBX7 (0.44) | DAOGABRPGABRDADORA3GABRA1 | |
| SCHEMBL639582 | 0.81 | PGR (0.42) | PGRMDM2MEN1KMT2AB3GNT2 | |
| SCHEMBL640608 | 0.81 | MDM2 (0.65) | DAOGABRPGABRDADORA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| CN-101528712-B | Substituted benzimidazolone derivatives, medicaments containing them and the use thereof | ABBOTT GMBH & CO KG | 2013-10-30 | — | — | CN | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| CN-101528712-A | Substituted benzimidazolone derivatives, medicaments containing them and the use thereof | ABBOTT GMBH & CO KG (DE) | 2009-09-09 | — | — | CN | disclosed |
| EP-2061769-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008025736-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | DAO 1622/4885GABRP 784/4885GABRD 1462/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | DAO 1622/4885GABRP 784/4885GABRD 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.